一个史蒂文 - 约翰逊综合征的病例是二次的Bumetanide
Fariyah Waseem1, Jainy Parikh1
1Medicine, Lancashire Teaching Hospital National Health Service (NHS) Foundation Trust, Preston, GBR.
Cureus
|November 19, 2025
概括
史蒂文-约翰逊综合征 (SJS) 是一种严重的药物反应,可能是由布米坦尼德引起的. 这份病例报告详细介绍了一名在服用布米坦尼德后患上SJS的患者,强调了及时诊断和治疗的重要性.
科学领域:
- 皮肤病学 皮肤病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 史蒂文-约翰逊综合征 (SJS) 是一种严重的皮肤不良反应 (SCAR),通常是由药物引起的.
- 含有硫胺的循环利尿剂Bumetanide与SCARs有关.
- 胀是一种常见的疾病,用于治疗心脏,肝脏和脏问题的布米坦胺.
研究的目的:
- 报告一个确认的SJS病例二次的布米坦尼德的管理.
- 要强调临床表现和管理布米坦尼德诱导的SJS.
主要方法:
- 病例报告详细介绍了一名64岁的男性患者.
- 临床观察和SJS的诊断.
- 鉴定和停止使用致病剂 (布米坦尼德).
主要成果:
- 患者在布梅坦尼德给药后经历了SJS.
- 迅速停止布梅他尼德和支持性护理有助于恢复.
- 这个案例证实了布米坦是SJS的潜在触发因素.
结论:
- 布梅坦尼德可以诱导严重的皮肤不良反应,如SJS.
- 早期识别和撤销违规药物对于患者的康复至关重要.
- 这一案例强调了在具有特征性症状的患者中考虑药物诱导的SJS的重要性.
相关概念视频
Drugs for Treatment of Constipation-Predominant IBS
682
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
682
Drugs for Treatment of Ulcerative Colitis in IBD
435
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
435
Drugs for Treatment of Diarrhea-Predominant IBS
604
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
604
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
1.3K
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
1.3K
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
224
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
224
Drug Metabolism: Phase II Reactions
4.8K
Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...
4.8K


